Evidence map›Paper›PMID 22821944›Full record

ArticleAmerican journal of physiology. Gastrointestinal and liver physiology2012

Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation.

Jasmohan S Bajaj, Phillip B Hylemon, Jason M Ridlon, Douglas M Heuman, Kalyani Daita, Melanie B White, Pamela Monteith, Nicole A Noble, Masoumeh Sikaroodi, Patrick M Gillevet

Registry-linked trialAbstract read
In one paragraph

Article in American journal of physiology. Gastrointestinal and liver physiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07102979 (Remedial Mechanisms of Simvastatin and Ursodeoxycholic Acid in Liver Cirrhosis), which is not on this map. Cited by 315 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
315citing papers in PubMed, 7 pooled it
13.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07102979 naterminatednot on this mapstarted 2024, after this paper: background citation

Remedial Mechanisms of Simvastatin and Ursodeoxycholic Acid in Liver Cirrhosis: Crosstalk Between Bile Secretion, Gut Microbiome, and Host Immune Response

TypeinterventionalSponsorChang Gung Memorial HospitalRan2024 to 2025Enrolled19ConditionsLiver FibrosisArmsUrsodeoxycholic Acid (URSO), Simvastatin
3 · Its place in the literature

Who cites it

315 citing papers in PubMed, 7 syntheses or guidelines pooled it, 526 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Clinical microbiology reviews · 2025
    Review
  17. A Review of Recent Advances in Fecal Microbiota Transplantation for the Treatment of Hepatic Encephalopathy.Medical science monitor : international medical journal of experimental and clinical research · 2025
    Review
  18. Article
  19. Article
  20. Review

255 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Jasmohan S BajajDivision of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University, Richmond, 23249, USA. jsbajaj@vcu.edu
Phillip B Hylemon
Jason M Ridlon
Douglas M Heuman
Kalyani Daita
Melanie B White
Pamela Monteith
Nicole A Noble
Masoumeh Sikaroodi
Patrick M Gillevet
George Mason University · USVirginia Commonwealth University · USHunter Holmes McGuire VA Medical Center · US

Funding

Spectrum of Neuro-Cognitive Impairment in CirrhosisR01DK087913 · NIDDK · VIRGINIA COMMONWEALTH UNIVERSITY · PI BAJAJ, JASMOHAN S · 2011 to 2015
$2.0M
Hepatic Encephalopathy in Alcoholic Cirrhosis: A Systems Biology ApproachR01AA020203 · NIAAA · VIRGINIA COMMONWEALTH UNIVERSITY · PI BAJAJ, JASMOHAN S · 2010 to 2012
$1.0M
Probiotic Yogurt for the Treatment of Minimal Hepatic EncephalopathyU01AT004428 · NCCIH · VIRGINIA COMMONWEALTH UNIVERSITY · PI BAJAJ, JASMOHAN S · 2009 to 2011
$848k
NCCIH NIH HHS UO1-AT004428NIAAA NIH HHS R01AA020203NIDDK NIH HHS R01 DK087913NIDDK NIH HHS R01DK087913
6 · The paper itself

Abstract

Although hepatic encephalopathy (HE) is linked to the gut microbiota, stool microbiome analysis has not found differences between HE and no-HE patients. This study aimed to compare sigmoid mucosal microbiome of cirrhotic patients to controls, between HE vs. no-HE patients, and to study their linkage with cognition and inflammation. Sixty cirrhotic patients (36 HE and 24 no-HE) underwent cognitive testing, stool collection, cytokine (Th1, Th2, Th17, and innate immunity), and endotoxin analysis. Thirty-six patients (19 HE and 17 no-HE) and 17 age-matched controls underwent sigmoid biopsies. Multitag pyrosequencing (including autochthonous genera, i.e., Blautia, Roseburia, Fecalibacterium, Dorea) was performed on stool and mucosa. Stool and mucosal microbiome differences within/between groups and correlation network analyses were performed. Controls had significantly higher autochthonous and lower pathogenic genera compared with cirrhotic patients, especially HE patients. HE patients had worse MELD (model for end-stage liver disease) score and cognition and higher IL-6 and endotoxin than no-HE. Mucosal microbiota was different from stool within both HE/no-HE groups. Between HE/no-HE patients, there was no difference in stool microbiota but mucosal microbiome was different with lower Roseburia and higher Enterococcus, Veillonella, Megasphaera, and Burkholderia abundance in HE. On network analysis, autochthonous genera (Blautia, Fecalibacterium, Roseburia, and Dorea) were associated with good cognition and decreased inflammation in both HE/no-HE, whereas genera overrepresented in HE (Enterococcus, Megasphaera, and Burkholderia) were linked to poor cognition and inflammation. Sigmoid mucosal microbiome differs significantly from stool microbiome in cirrhosis. Cirrhotic, especially HE, patients' mucosal microbiota is significantly different from controls with a lack of potentially beneficial autochthonous and overgrowth of potentially pathogenic genera, which are associated with poor cognition and inflammation.

Indexed as

AdultBacteriaCognitionColonFecesFemaleHepatic EncephalopathyHumansInflammationIntestinal MucosaLiver CirrhosisMaleMiddle Aged

Identifiers

PMID22821944
PMCPMC3468538
OpenAlexW2005429741

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.